A Phase II Evaluation of Gefitinib in the Treatment of Persistent or Recurrent Endometrial Cancer: A Gynecologic Oncology Group Study

BACKGROUND: A phase II trial was performed to evaluate the efficacy and safety of gefitinib in patients with persistent/recurrent endometrial cancer. METHODS: Women with histologically confirmed persistent/recurrent endometrial cancer were treated with 500 mg oral gefitinib daily until progression o...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Leslie, Kimberly K., Sill, Michael W., Fischer, Edgar, Darcy, Kathleen M., Mannel, Robert S., Tewari, Krishnansu S., Hanjani, Parviz, Wilken, Jason A., Baron, Andre T., Godwin, Andrew K., Schilder, Russell J., Singh, Meenakshi, Maihle, Nita J.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2013
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3700732/
https://ncbi.nlm.nih.gov/pubmed/23438670
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2013.02.019
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares